Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Filed pursuant to Rule 433

Registration Statement No. 333-180300-03

FINANCIAL PRODUCTS

FACT SHEET (K403)

Offering Period: March 28, 2014– April 26, 2014
3.5 Year Buffered Accelerated Return Equity Securities (BARES)
Linked to the S&P 500 ^® Index

Product Summary

•

3.5 year Buffered Accelerated Return Equity Securities (BARES) linked to the performance of the S&P 500 ^® Index.

•

If the Final Level is equal to or greater than the Initial Level, then you will be entitled to an amount equal to the Fixed Payment Percentage.

•

If the Final Level is less than the Initial Level by not more than the Buffer Amount, then you will be entitled to receive the principal amount at maturity.

•

If the Final Level is less than the Initial Level by more than the Buffer Amount, then you will be exposed to any depreciation in the Underlying beyond the Buffer Amount.

•

Any payment on the securities is subject to our ability to pay our obligations as they become due.

•

Credit Suisse currently estimates that the value of the securities on the Trade Date will be less than the price you pay for the securities, reflecting the deduction of underwriting discounts and commissions and other costs creating and marketing the securities.

Terms

Issuer:	Credit Suisse AG (“Credit Suisse”), acting through one of its branches
Trade Date:	Expected to be April 28, 2014
Settlement Date:	Expected to be April 30, 2014
Underlying:	The S&P 500 ^® Index.
Fixed Payment Percentage*:	Expected to be between 15.5% and 18.5%.
Redemption Amount:	Principal Amount x (1 + Underlying Return).
Underlying Return:	If (a) the Final Level is equal to or greater than the Initial Level, then: the Fixed Payment Percentage; (b) the Final Level is less than the Initial Level by not more than the Buffer Amount, then: zero; (c) the Final Level is less than the Initial Level by more than the Buffer Amount, then: [(Final Level – Initial Level) / Initial Level] + Buffer Amount.
Buffer Amount:	20%
Initial Level:	The closing level on the Trade Date.
Final Level:	The closing level on the Valuation Date.
Valuation Date:	October 30, 2017
Maturity Date:	November 1, 2017
CUSIP:	22547QLK0

*To be determined on the Trade Date.

Benefits

•

If the Final Level is greater than the Initial Level, you will be entitled to receive a Fixed Payment Percentage.

•

Reduced downside risk due to a Buffer Amount of 20%.

Hypothetical Returns at Maturity


Percentage Change
from Initial Level to	Underlying	Redemption Amount
Final Level of the	Return (1)(2)	per $1,000 Principal
Underlying		Amount (1)(2)
50%	17.0%	$1,170
40%	17.0%	$1,170
30%	17.0%	$1,170
20%	17.0%	$1,170
10%	17.0%	$1,170
0%	17.0%	$1,170
-10%	0.0%	$1,000
-20%	0.0%	$1,000
-30%	-10.0%	$900
-40%	-20.0%	$800
-50%	-30.0%	$700

(1)

Assumes a Fixed Payment Percentage of 17%* (the midpoint of the expected range)*.

(2)

The hypothetical Redemption Amounts set forth above are illustrative purposes only and may not be the actual returns applicable to you. The numbers appearing in the table have been rounded for ease of analysis.

Certain Product Risks

•

Your investment may result in a loss of up to 80% of the principal amount. The Redemption Amount will be less than the principal amount if the Final Level is less than the Initial Level by more than the Buffer Amount. In such case, you will be exposed to any depreciation in the Underlying beyond the Buffer Amount.

•

The value of the securities and the payment of any amount due on the securities are subject to the credit risk of Credit Suisse.

•

The securities do not pay interest.

•

The Underlying Return will not exceed the Fixed Payment Percentage regardless of the appreciation in the level of the Underlying, which may be significant.

(See “Additional Risk Considerations” on the next page.)

Product Profile

Horizon (years)		3.5 Years
Principal Repayment		Principal at Risk
Investment Objective		Appreciation
Market Outlook		Bullish

FINANCIAL PRODUCTS
FACT SHEET

Offering Period: March 28, 2014– April 26, 2014
3.5 Year Buffered Accelerated Return Equity Securities (BARES)

Additional Risk Considerations

•

Prior to maturity, costs such as concessions and hedging may affect the value of the securities.

•

Liquidity – The securities will not be listed on any securities exchange. Credit Suisse (or its affiliates) intends to offer to purchase the securities in the secondary market but is not required to do so. Many factors, most of which are beyond the control of the Issuer, will influence the value of the securities and the price at which the securities may be purchased or sold in the secondary market. For example, the creditworthiness of the Issuer, including actual or anticipated downgrades to the Issuer’s credit ratings, may be a contributing factor.

•

Potential Conflicts – We and our affiliates play a variety of roles in connection with the issuance of the securities including acting as calculation agent, hedging our obligations under the securities and determining the estimated value of the securities. The agent for this offering, Credit Suisse Securities (USA) LLC (“CSSU”), is our affiliate. In accordance with FINRA Rule 5121, CSSU may not make sales in this offering to any discretionary account without prior written approval of the customer.

•

The securities will be affected by a number of economic, financial, political, regulatory, and judicial factors that may either offset or magnify each other.

•

As a holder of the securities, you will not have voting rights or rights to receive cash dividends or other distributions with respect to the equity securities comprising the Underlying.

The risks set forth in the section entitled “Certain Product Risks” on the preceding page and this section “Additional Risk Considerations” are only intended as summaries of some of the risks relating to an investment in the securities. Prior to investing in the securities, you should, in particular, review the “Certain Product Risks” and “Additional Risk Considerations” sections herein, the “Selected Risk Considerations” section in the pricing supplement, and the “Risk Factors” section of the product supplement, which set forth risks related to an investment in the securities.

Disclaimer

IRS Circular 230 Disclosure: Credit Suisse and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters contained herein (including any attachments) is not intended or written to be used and cannot be used, in connection with the promotion, marketing or recommendation by anyone unaffiliated with Credit Suisse of any of the matters address herein or for the purpose of avoiding U.S. tax-related penalties.

Investment suitability must be determined individually for each investor, and the financial instruments described herein may not be suitable for all investors. The products described herein should generally be held to maturity as early sales could result in lower than anticipated returns. This information is not intended to provide and should not be relied upon as providing accounting, legal, regulatory or tax advice. Investors should consult with their own advisors as to these matters.

This material is not a product of Credit Suisse Research Departments. Financial Products may involve a high degree of risk, and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. Credit Suisse and its affiliates may have positions (long or short), effect transactions or make markets in securities or financial instruments mentioned herein (or options with respect thereto), or provide advice or loans to, or participate in the underwriting or restructuring of the obligations, issuers of the stocks comprising the applicable index, indices or fund mentioned herein. Credit Suisse is a member of FINRA, NYSE and SIPC. Clients should contact their salespersons at, and execute transactions through, a Credit Suisse entity qualified in their home jurisdiction unless governing law permits otherwise.

You may revoke your offer to purchase the securities at any time prior to the time at which we accept such offer on the date the securities are priced. We reserve the right to change the terms of, or reject any offer to purchase the securities prior to their issuance. In the event of any changes to the terms of the securities, we will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which case we may reject your offer to purchase.

This document is a summary of the terms of the securities and factors that you should consider before deciding to invest in the securities. Credit Suisse has filed a registration statement (including pricing supplement, product supplement, underlying supplement, prospectus supplement and prospectus) with the Securities and Exchange Commission, or SEC, for the offering to which this offering summary relates. Before you invest, you should read this summary together with the Preliminary Pricing Supplement dated March 28, 2014, Underlying Supplement dated July 29, 2013, Product Supplement No. AK-I dated March 23, 2012, Prospectus Supplement dated March 23, 2012 and Prospectus dated March 23, 2012 to understand fully the terms of the notes and other considerations that are important in making a decision about investing in the securities. You may get these documents without cost by visiting EDGAR on the SEC Web site at www.sec.gov . Alternatively, Credit Suisse, any agent or any dealer participating in this offering will arrange to send you the pricing supplement, product supplement, underlying supplement, prospectus supplement and prospectus if you so request by calling toll-free 1 (800) 221-1037.

You may access the pricing supplement related to the offering summarized herein on the SEC website at: http://www.sec.gov/Archives/edgar/data/1053092/000095010314002198/dp45183_424b2-k403.htm

You may access the underlying supplement, product supplement, prospectus supplement and prospectus on the SEC website at www.sec.gov or by clicking on the hyperlinks to each of the respective documents incorporated by reference in the pricing supplement.